drugset / Trial / NCT00748501
Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS)
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of the study is to evaluate the effects of the investigational drug, SB-509 on progression of the disease in subjects with ALS
Timeline
- Start
- 2008-09
- Primary completion
- 2010-06
- Completion
- 2010-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | SB-509 | Unknown | 60 mg | Intramuscular |